South African pharmaceutical company Aspen Pharmacare has revealed that they have reached an initial agreement with Johnson & Johnson to commercially release Covid-19 vaccine candidates.
In addition, the largest pharmaceutical company in the country says it has agreed to provide the capacity required for the manufacture of J&J vaccine candidates, who are still in clinical trials, in Port Elizabeth.
Under the agreement, Aspen will play a role in the formulation, filling and packaging of vaccines for U.S. companies.
Accordingly, Aspen shares are said to have registered more than 4% on the Johannesburg Stock Exchange.
In addition, more than $ 184.2 million has been invested by the company at the Port Elizabeth facility. In addition, vaccine candidate production locations are alleged to have the ability to produce more than 300 million doses a year.
For all you know, South Africa has recorded more than 726,000 cases of coronavirus infection, the highest number on the African continent, with more than 19,400 deaths reported.
Subsequently, the country is rumored to have conducted at least 4 potential clinical trials of the Covid-19 vaccine, including J&J candidates.
Meanwhile, the agreement between Aspen and J&J depends on certain technology transfer activities and commercial conditions.
Last month, the South African Biovac Institute, a joint venture between the government and the private sector, held talks to produce several vaccines needed by the country for protection from Covid-19.
